-+ 0.00%
-+ 0.00%
-+ 0.00%

J&J - RYBREVANT PLUS CHEMOTHERAPY DELIVERS LONGEST REPORTED MEDIAN OVERALL SURVIVAL IN EGFR EXON 20 INSERTION NSCLC

Reuters·09/14/2026 01:46:12

Please log in to view news